Huntington's disease / edited by Thomas N. Chase, Nancy S. Wexler, André Barbeau.
- Date:
- 1979
Licence: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Credit: Huntington's disease / edited by Thomas N. Chase, Nancy S. Wexler, André Barbeau. Source: Wellcome Collection.
849/856 page 817
![SUBJECT INDEX 817 Phospholipid(s) {contd.) tritiated G AB A binding and, 705-715 Physiological considerations in pharmacology of HD, 679-681 Physiology of basal ganglia, 137-149 Physostigmine effects in learning experiments, 221 К A animal model and, 597 PD and, 454 Pick's disease, 89 Piribedil, treatment of HD with, 759-762 Pituitary gland blockage of prolactin by dopamine in, 306-311 hypothalamus and, hormonal and neuronal relationships between, 291 Pituitary-hypothalamic function as diagnostic tool, Ml Pituitary-hypothalamic hormonal regulation in HD, 305-315 Placebo effects of DA drugs on GH and PRL and, 323, 330 effects in learning experiments, 221, 222 Plasma, free fatty acids in, 293 Plating of cells, 352 Pneumoencephalogram (PEG) as diagnostic tool, 182 Point prevalence data for HD, 20-21 Polyacrylamide gel electrophoresis of recon¬ stituted erythrocyte membrane particles, 411 Poly amines, 539, 541 in cortical biopsies, 537-545 in frontal cortex, 539 Polymorphism(s) chromosomal, analysis of, 42 filament and fibril, 101, 104 of intranuclear ultrastructures, 104 Population doublings per week, 352-354, 356 Postmortem brain tissue, dopamine in, 481- 490 Postsynaptic dopaminergic activity, chorea and,752 Postsynaptic sites, agents that mimic GABA at, 728 Potassium efflux from erythrocytes, 392 Presymptomatic test, motor unit control as, 163-175 Prevalence of affective disturbance, 196 definition of, 4,13 of HD in Australian population, 74 Prevalence surveys, 5 problems of, 18 Primary abnormality, 8 Primary death rates, 15, 16 Primates, awake, studies of, 144-149 PRL, see Prolactin Probable disease, 44 Processing, semantic and acoustic, 219 Prodromal phase of HD, 198 Progression in autoaggressive disease, 44-46 hypotheses of, 48-53 Progressive supranuclear palsy (PSP), 180 Prolactin (PRL), hypothalamic function and, 292 Prolactin levels apomorphine and, 325-326 bromocriptine and, 324, 325 domperidone and, 328 L-DOPA and, 301, 326 dopamine and, 327, 328 after glucose administration, 300 hyperglycemia and, 301 isoniazid and, 797-800 phenothiazines and, 306 placebo and, 330 plasma, 324-326 sulpiride and, 329 TRH and, 329 Prolactin responses, 205 Prolactin secretion effects of CPZ on, 307, 309, 311 effects of DA drugs on, 319-332 L-DOPA and glucose influence on, 299- 303 TRH and, 306-308,310,311 Propranolol in treatment of HD, 777-782 Protein(s) integral, 398 membrane, 398 mutant, in HD and schizophrenia, 335-348 radiolabeled, 361-369 Protein components necessary for antibody absorption, 438440 Protein glycosylation, 375-381, 397 by direct measurement of [^^C]glucosamine incorporation, 375-381 inhibition of, by glutamine, 381-383 Protein kinase, membrane-bound, HD erythro¬ cytes and, 404 Protein levels, KA intrastriatal injections and, 584 Protein studies in HD, 451-452 Protein synthesis cell density and, 365 measurement of, 364 Psychiatric disorders, 285-286 frequency of, 282 onset of, 283 treatment response and, 285-286 types of, 283-284](https://iiif.wellcomecollection.org/image/b18021888_0850.JP2/full/800%2C/0/default.jpg)
